Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Insider Filings - BARRETT M JAMES
Last Updated 
24-Mar-17
Enter symbol:
symbol lookup

 

EDGAR Online: Get a Free Trial to EDGAR Online Premium | Full text Search

BARRETT M JAMES: Declared Holdings
Company/RelationshipReportedShares  Ownership
Adaptimmune Therapeutics plc -
Beneficial Owner (10% or more)
NasdaqGS:ADAP
(historical quotes, profile, other insiders)
1-Jan-1659,269,000  Indirect
Ardelyx, Inc.
Beneficial Owner (10% or more)
NasdaqGM:ARDX
(historical quotes, profile, other insiders)
18-Jul-168,752,543  Indirect
Epizyme, Inc.
Beneficial Owner (10% or more)
NasdaqGS:EPZM
(historical quotes, profile, other insiders)
12-Jan-166,260,851  Indirect
GlycoMimetics, Inc.
Director
NasdaqGM:GLYC
(historical quotes, profile, other insiders)
16-Nov-158,584,128  Indirect
INTERLEUKIN GENETI COM USD0.001
Beneficial Owner (10% or more)
Other OTC:ILIU
(historical quotes, profile, other insiders)
29-Jul-1655,418,811  Indirect
Mirna Therapeutics, Inc.
Beneficial Owner (10% or more)
NasdaqGM:MIRN
(historical quotes, profile, other insiders)
6-Oct-152,971,517  Indirect
MuleSoft, Inc. Class A
Beneficial Owner (10% or more)
NYSE:MULE
(historical quotes, profile, other insiders)
22-Mar-170  Indirect
Proteostasis Therapeutics, Inc.
Director
NasdaqGM:PTI
(historical quotes, profile, other insiders)
14-Sep-163,554,610  Indirect
Ra Pharmaceuticals, Inc.
Beneficial Owner (10% or more)
NasdaqGM:RARX
(historical quotes, profile, other insiders)
31-Oct-163,490,073  Indirect
Senseonics Holdings, Inc.
Director
NYSE MKT:SENS
(historical quotes, profile, other insiders)
17-Mar-16
23-Mar-16
494,689
   14,971,064
15,465,753
  Direct
  Indirect  
  Total
Supernus Pharmaceuticals, Inc.
Director
NasdaqGM:SUPN
(historical quotes, profile, other insiders)
16-Mar-16
8-Dec-15
97,355
   115,355
212,710
  Direct
  Indirect  
  Total
TRACON Pharmaceuticals, Inc.
Beneficial Owner (10% or more)
NasdaqGM:TCON
(historical quotes, profile, other insiders)
29-Nov-162,758,039  Indirect
TESARO, Inc.
Beneficial Owner (10% or more)
NasdaqGS:TSRO
(historical quotes, profile, other insiders)
1-Jun-15
18-Mar-16
252
   9,564,936
9,565,188
  Direct
  Indirect  
  Total
Vitae Pharmaceuticals, Inc.
Beneficial Owner (10% or more)
NasdaqGS:VTAE
(historical quotes, other insiders)
1-Jul-15
1-Jul-15
464
   1,787,698
1,788,162
  Direct
  Indirect  
  Total
Zosano Pharma Corporation
Beneficial Owner (10% or more)
NasdaqCM:ZSAN
(historical quotes, profile, other insiders)
13-Feb-17952,809  Indirect

Insider & restricted shareholder transactions reported over the last two years
DateSharesStockTransaction
22-Mar-17 *12,679,970MULE Disposition (Non Open Market)
22-Mar-17 *12,359,190MULE Acquisition (Non Open Market)
16-Mar-17 *320,780MULE Statement of Ownership
13-Feb-17 *1,099,996ZSAN Sale at $2.01 per share.
(Proceeds of $2,210,991)
29-Nov-16 *869,565TCON Purchase at $5.75 per share.
(Cost of $4,999,998)
31-Oct-16 *435RARX Sale at $13 per share.
(Proceeds of $5,655)
31-Oct-16 *3,071,388RARX Acquisition (Non Open Market)
31-Oct-16 *338,462RARX Purchase at $13 per share.
(Cost of $4,400,006)
31-Oct-16 *80,658RARX Option Exercise at $0.07 per share.
(Cost of $5,646)
16-Sep-16 *7,471ZSAN Sale at $0.75 per share.
(Proceeds of $5,603)
14-Sep-16 *461,538PTI Purchase at $13 - $13 per share.
(Cost of about $6,000,000)
13-Sep-16 *10,000ZSAN Sale at $0.74 - $0.74 per share.
(Proceeds of about $7,400)
29-Aug-16 *50,000ZSAN Sale at $1.01 - $1.01 per share.
(Proceeds of about $51,000)
24-Aug-16 *1,200ZSAN Sale at $1.21 - $1.21 per share.
(Proceeds of about $1,452)
29-Jul-16 *20,120,724ILIU Purchase at $0.10 - $0.1 per share.
(Cost of about $2,012,000)
21-Jul-16 *8,989ZSAN Sale at $1.33 - $1.33 per share.
(Proceeds of about $12,000)
20-Jul-16 *14,158ZSAN Sale at $1.24 - $1.24 per share.
(Proceeds of about $18,000)
19-Jul-16 *534ZSAN Sale at $1.17 - $1.17 per share.
(Proceeds of about $624)
18-Jul-16 *763,650ARDX Purchase at $8.73 - $8.73 per share.
(Cost of about $6,667,000)
13-Jul-16 *13,382ZSAN Sale at $1.20 - $1.2 per share.
(Proceeds of about $16,000)
23-Mar-16 *1,578,947SENS Purchase at $2.85 - $2.85 per share.
(Cost of about $4,500,000)
18-Mar-16 *710,429TSRO Purchase at $35.19 - $35.19 per share.
(Cost of about $25,000,000)
17-Mar-16 494,689SENS Statement of Ownership
17-Mar-16 *13,392,117SENS Statement of Ownership
16-Mar-16 18,000SUPN Disposition (Non Open Market) at $0 per share.
17-Feb-16 *2,192,748PTI Acquisition (Non Open Market)
17-Feb-16 *900,324PTI Purchase at $8 - $8 per share.
(Cost of about $7,203,000)
13-Jan-16 *500,000ARDX Purchase at $10 - $10 per share.
(Cost of about $5,000,000)
12-Jan-16 *1,111,111EPZM Purchase at $9 - $9 per share.
(Cost of about $10,000,000)
1-Jan-16 *59,269,000ADAP Statement of Ownership
8-Dec-15 *70,913SUPN Sale at $14.75 - $14.75 per share.
(Proceeds of about $1,046,000)
7-Dec-15 *71,067SUPN Sale at $14.38 - $14.38 per share.
(Proceeds of about $1,022,000)
4-Dec-15 *70,990SUPN Sale at $14.54 - $14.54 per share.
(Proceeds of about $1,032,000)
3-Dec-15 *4,993,557SUPN Disposition (Non Open Market) at $0 per share.
3-Dec-15 *1,427,328SUPN Acquisition (Non Open Market) at $0 per share.
3-Dec-15 41,426SUPN Acquisition (Non Open Market) at $0 per share.
25-Nov-15 16,179SUPN Sale at $16.35 - $16.35 per share.
(Proceeds of about $265,000)
25-Nov-15 16,179SUPN Option Exercise at $7.90 - $9.24 per share.
(Cost of about $139,000)
18-Nov-15 *43,000SUPN Sale at $16.50 - $16.5 per share.
(Proceeds of about $710,000)
17-Nov-15 *50,000SUPN Sale at $16.71 - $16.71 per share.
(Proceeds of about $836,000)
16-Nov-15 *9,445GLYC Option Exercise at $0.33 - $0.33 per share.
(Cost of about $3,116)
16-Nov-15 *452GLYC Sale at $6.91 - $6.91 per share.
(Proceeds of about $3,123)
16-Nov-15 *19,650SUPN Sale at $16.13 - $16.13 per share.
(Proceeds of about $317,000)
13-Nov-15 *100,000SUPN Sale at $16.26 - $16.26 per share.
(Proceeds of about $1,626,000)
11-Nov-15 *4,993,557SUPN Disposition (Non Open Market) at $0 per share.
11-Nov-15 41,405SUPN Acquisition (Non Open Market) at $0 per share.
11-Nov-15 *1,426,987SUPN Acquisition (Non Open Market) at $0 per share.
6-Oct-15 *857,142MIRN Purchase at $7 - $7 per share.
(Cost of about $6,000,000)
6-Oct-15 *289,166MIRN Acquisition (Non Open Market) at $0 per share.
5-Oct-15 *1,825,209MIRN Acquisition (Non Open Market)
1-Jul-15 464VTAE Acquisition (Non Open Market) at $0 per share.
1-Jul-15 *9,384VTAE Acquisition (Non Open Market) at $0 per share.
1-Jul-15 *833,250VTAE Disposition (Non Open Market) at $0 per share.
17-Jun-15 *111,881SUPN Sale at $16.02 - $16.67 per share.
(Proceeds of about $1,829,000)
16-Jun-15 *55,105SUPN Sale at $16.85 - $16.85 per share.
(Proceeds of about $929,000)
15-Jun-15 32,524SUPN Acquisition (Non Open Market) at $0 per share.
15-Jun-15 *3,921,000SUPN Disposition (Non Open Market) at $0 per share.
15-Jun-15 *1,120,510SUPN Acquisition (Non Open Market) at $0 per share.
5-Jun-15 *1,869,159ARDX Purchase at $10.70 - $10.7 per share.
(Cost of about $20,000,000)
2-Jun-15 *2,129TSRO Sale at $57.55 - $58.13 per share.
(Proceeds of about $123,000)
1-Jun-15 252TSRO Acquisition (Non Open Market) at $0 per share.
1-Jun-15 *1,010,000TSRO Disposition (Non Open Market) at $0 per share.
1-Jun-15 *12,381TSRO Acquisition (Non Open Market) at $0 per share.
    * Indicates that some (or all) shares are held indirectly (e.g. in a trust, by a spouse, etc.)



EDGAR Online: Get a Free Trial to EDGAR Online Premium | Full text Search


Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Data and information are provided by EDGAR Online, Inc. for informational purposes only and not intended for trading purposes. Yahoo!, EDGAR Online, Inc. shall have no liability for the accuracy of the information furnished or for delays, omissions or opinions expressed therein. You may not use the information for any illegal purpose or furnish the information to any person, firm, or branch office for commercial re-use or re-sale.

Questions or Comments?